Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1431-1438

  Armistead, Paul M ^a,c   de Lima, Marcos ^a   Pierce, Sherry ^a   Qiao, Wei ^a   Wang, Xuemei ^a   Thall, Peter F ^a   Giralt, Sergio ^a   Ravandi, Farhad ^a   Kantarjian, Hagop ^a   Champlin, Richard ^a   Estey, Elihu ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Hematopoietic stem cell transplantation; Overall survival; Relapsed acute myelogenous leukemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE;

EID: 70350619986     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.008     Document Type: Article

References (14)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368: 1894-1907.
2. Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer. 2007.
3. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969-1978.
4. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced-stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26: 1157-1163.
5. Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108-114.
6. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476-479.
7. Randles R, Wolfe D. Introduction to the Theory of Nonparametric Statistics. New York: Wiley; 1979. 1.
8. 2 from contingency tables, and the calculation of p. J R Stat Soc. 1922;85:87-94.
9. Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163-170.
11. Jennison C, Turnbull B. Group-Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2000.
12. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865-872.
13. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113:1631-1638.
14. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14:282-289.